Focused On-demand Library for Small ribosomal subunit protein uS11m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P82912

UPID:

RT11_HUMAN

Alternative names:

28S ribosomal protein S11, mitochondrial; Cervical cancer proto-oncogene 2 protein

Alternative UPACC:

P82912; B2RD52; Q969D7; Q96GI3; Q9BYC3

Background:

The Small ribosomal subunit protein uS11m, also known as 28S ribosomal protein S11, mitochondrial and Cervical cancer proto-oncogene 2 protein, plays a crucial role in mitochondrial protein synthesis. This protein is a component of the small ribosomal subunit, which is essential for the translation of messenger RNA into amino acids, a fundamental process in cellular metabolism and function.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS11m could open doors to potential therapeutic strategies. Its involvement in protein synthesis makes it a potential target for interventions in diseases where protein synthesis is dysregulated.